Lumos Diagnostics Secures Funding for FebriDx® Test

Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.

Lumos Diagnostics has partnered with BARDA, receiving nearly $3 million in non-dilutive funding, to support the CLIA waiver study and FDA application for its FebriDx® test, which helps clinicians determine whether respiratory infections are bacterial or non-bacterial. The partnership could extend the use of the rapid, point-of-care FebriDx® test to various outpatient settings, potentially improving antibiotic stewardship. The total contract value could reach over $8 million if all options are exercised, advancing Lumos’ mission to enhance diagnostic capabilities directly at the point of care.

For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.